In early results from a phase 1 trial, Corvus Pharmaceuticals’ investigational monoclonal antibody CPI-006 showed promise as a COVID-19 treatment.

All 10 patients who received either a 0.3-mg dose or a 1-mg dose of the drug produced high levels of antibodies to the SARS-CoV-2 virus within seven days of a single infusion. The patients also experienced clinical improvement and experienced no drug-related safety issues.

Corvus is also investigating CPI-006 as an immunotherapy for cancer and infectious disease.